ECSP19011185A - Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123 - Google Patents

Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123

Info

Publication number
ECSP19011185A
ECSP19011185A ECSENADI201911185A ECDI201911185A ECSP19011185A EC SP19011185 A ECSP19011185 A EC SP19011185A EC SENADI201911185 A ECSENADI201911185 A EC SENADI201911185A EC DI201911185 A ECDI201911185 A EC DI201911185A EC SP19011185 A ECSP19011185 A EC SP19011185A
Authority
EC
Ecuador
Prior art keywords
specifically bind
antibody
binding proteins
bispecific antibody
binding protein
Prior art date
Application number
ECSENADI201911185A
Other languages
English (en)
Inventor
Wulf-Dirk Leuschner
Peter Wonerow
Stephane Guerif
Jana Albrecht
Katja Kroll
Jochen Beninga
Marion Schneider
Ercole Rao
Christian Lange
Christian Beil
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP19011185A publication Critical patent/ECSP19011185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a proteínas de unión de tipo anticuerpo que se unen específicamente a CD3 y CD123. La invención también se refiere a composiciones farmacéuticas que comprenden dicha proteína de unión de tipo anticuerpo y al uso de dichas composiciones farmacéuticas y proteína de unión de tipo anticuerpo para tratar el cáncer. La invención se refiere además a ácidos nucleicos aislados, vectores y células huésped que comprenden una secuencia que codifica dicha proteína de unión de tipo anticuerpo.
ECSENADI201911185A 2016-07-18 2019-02-15 Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123 ECSP19011185A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305923 2016-07-18

Publications (1)

Publication Number Publication Date
ECSP19011185A true ECSP19011185A (es) 2019-02-28

Family

ID=56507555

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201911185A ECSP19011185A (es) 2016-07-18 2019-02-15 Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123

Country Status (24)

Country Link
US (1) US20190241657A1 (es)
EP (1) EP3484924A1 (es)
JP (2) JP7071329B2 (es)
KR (1) KR20190028771A (es)
CN (1) CN109715665A (es)
AR (1) AR109264A1 (es)
AU (1) AU2017299125A1 (es)
BR (1) BR112019000770A2 (es)
CA (1) CA3030943A1 (es)
CL (1) CL2019000119A1 (es)
CO (1) CO2019001367A2 (es)
CR (1) CR20190072A (es)
DO (1) DOP2019000011A (es)
EA (1) EA201990321A1 (es)
EC (1) ECSP19011185A (es)
IL (1) IL264248A (es)
MA (1) MA45680A (es)
MX (1) MX2019000844A (es)
PE (1) PE20190514A1 (es)
PH (1) PH12019500122A1 (es)
SG (1) SG11201900400QA (es)
TN (1) TN2019000015A1 (es)
TW (1) TWI790206B (es)
WO (1) WO2018015340A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60916B1 (sr) 2015-01-23 2020-11-30 Sanofi Sa Anti-cd3 antitela, anti-cd123 antitela i bispecifična antitela koja se specifično vezuju za cd3 i/ili cd123
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
BR112021008283A2 (pt) * 2018-10-30 2021-09-14 Macrogenics, Inc. Método de tratamento de uma malignidade hematológica quimiorrefratária em um paciente, e método para determinar se um paciente seria um respondedor adequado ao uso de uma molécula biespecífica cd123 x cd3 para tratar uma malignidade hematológica
MA55305A (fr) * 2019-03-11 2022-01-19 Janssen Biotech Inc Anticorps bispécifiques anti-v béta 17/anti-cd123
CN111171155B (zh) 2020-02-05 2021-02-19 北京智仁美博生物科技有限公司 抗cd3和cd123双特异性抗体及其用途
TW202200619A (zh) * 2020-03-17 2022-01-01 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
MX2023002948A (es) 2020-09-11 2023-05-22 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadena beta.
CN116963774A (zh) 2021-01-28 2023-10-27 瑞泽恩制药公司 用于治疗细胞因子释放综合征的组合物和方法
CN113368232B (zh) * 2021-06-02 2022-08-26 上海交通大学 多特异性抗原结合蛋白及其应用
CA3224408A1 (en) * 2021-08-06 2023-02-09 Rosalba LEPORE Discernible cell surface protein variants for use in cell therapy
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
DE69032484D1 (de) 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
IL100460A (en) 1990-12-20 1997-06-10 Ixsys Method for optimization of binding proteins and nucleic acids encoding a binding protein produced thereby
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
EP1071752B1 (en) 1998-04-21 2003-07-09 Micromet AG CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
JP2004509835A (ja) 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物
ES2672769T3 (es) 2007-08-29 2018-06-18 Sanofi Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
NZ591087A (en) * 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UA116192C2 (uk) * 2011-08-23 2018-02-26 Рош Глікарт Аг Активуюча т-клітини біоспецифічна антигензв'язуюча молекула
US9745381B2 (en) * 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
KR20160089390A (ko) * 2013-12-10 2016-07-27 에프. 호프만-라 로슈 아게 다중-하부단위 구조에 대한 약학적 활성 개체의 표적화 전달을 위한 다중-하부단위 구조의 하부단위의 결합 도메인의 용도
JP6805130B2 (ja) * 2014-09-05 2020-12-23 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用
CU24597B1 (es) * 2014-11-26 2022-05-11 Xencor Inc Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
RS60916B1 (sr) * 2015-01-23 2020-11-30 Sanofi Sa Anti-cd3 antitela, anti-cd123 antitela i bispecifična antitela koja se specifično vezuju za cd3 i/ili cd123

Also Published As

Publication number Publication date
EA201990321A1 (ru) 2019-06-28
SG11201900400QA (en) 2019-02-27
TN2019000015A1 (en) 2020-07-15
AR109264A1 (es) 2018-11-14
US20190241657A1 (en) 2019-08-08
PE20190514A1 (es) 2019-04-10
EP3484924A1 (en) 2019-05-22
CO2019001367A2 (es) 2019-02-19
CR20190072A (es) 2019-06-25
DOP2019000011A (es) 2019-05-15
TWI790206B (zh) 2023-01-21
CA3030943A1 (en) 2018-01-25
TW201811830A (zh) 2018-04-01
KR20190028771A (ko) 2019-03-19
IL264248A (en) 2019-02-28
JP2019531701A (ja) 2019-11-07
CL2019000119A1 (es) 2019-06-14
JP7071329B2 (ja) 2022-05-18
PH12019500122A1 (en) 2019-04-15
MX2019000844A (es) 2019-07-04
MA45680A (fr) 2019-05-22
AU2017299125A1 (en) 2019-03-07
BR112019000770A2 (pt) 2019-07-02
CN109715665A (zh) 2019-05-03
WO2018015340A1 (en) 2018-01-25
JP2022105138A (ja) 2022-07-12

Similar Documents

Publication Publication Date Title
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
MX2020004027A (es) Anticuerpos especificos cd47/pd-l1.
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
UY35964A (es) Anticuerpos humanos para pd?1
CR20170079A (es) Agentes de unión a cd123 y usos de estos
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
AR100427A1 (es) PROTEÍNAS DE UNIÓN A ANTÍGENO DE HER1 QUE SE UNEN A LA HORQUILLA b DE HER1
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
TW202417514A (zh) 雙特異性結合蛋白及其用途
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения
AR102872A1 (es) Anticuerpos anti-pd-1 y sus métodos de uso